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OBJECTIVES We sought to investigate whether the combination of an oral endothelin (ET)A receptor
antagonist and an oral prostacyclin (PGI2) analogue is superior to the single use of each drug
alone for treating pulmonary hypertension (PH).
BACKGROUND Treatment with intravenous PGI2 or an ETA receptor antagonist was effective for PH;
however, the effect of both agents is unclear.
METHODS We administered the oral ETA receptor antagonist TA-0201 and/or the oral PGI2 analogue
beraprost sodium (BPS) to rats with monocrotaline-induced PH for 19 days. The groups
were: normal rats with vehicle treatment (Control group), PH rats with vehicle treatment
(PH group), PH rats with TA-0201 treatment (PH  TA group), PH rats with BPS
treatment (PH  BPS group) and PH rats with TA-0201 and BPS treatment (PH  TA 
BPS group).
RESULTS Right ventricular (RV) systolic pressure and the ratio of RV systolic pressure to systemic
systolic blood pressure (Pp/Ps) were markedly higher in the PH group than in the Control
group. The increased RV systolic pressure and Pp/Ps were significantly and comparably
depressed in the PH  TA and PH  BPS groups; it was more greatly depressed in the
PH  TA  BPS group than in the groups with each drug alone. The indexes of RV
hypertrophy showed the same tendency as the increase in RV systolic pressure among the five
groups. The expression of beta-myosin heavy chain messenger ribonucleic acid in the RV was
markedly augmented in the PH group; the enhancement was inhibited in the PH  TA 
BPS group to the greatest degree. Medial wall thickness of the pulmonary artery was
markedly increased in the PH group; the increase was depressed in the PH  TA  BPS
group. Combined treatment also ameliorated PH, even if it started after the onset of PH.
CONCLUSIONS The combination of an oral ETA receptor antagonist and an oral PGI2 analogue is superior
to the single use of each drug alone in inhibiting the progression of PH. (J Am Coll Cardiol
2002;40:175–81) © 2002 by the American College of Cardiology Foundation
Pulmonary hypertension (PH) is a disease associated with a
poor prognosis; it is resistant to drug treatment and is
characterized by the progressive elevation of pulmonary
artery pressure and pulmonary vascular resistance, ultimately
producing right ventricular (RV) failure and leading to
death (1). Previously, a variety of drugs have been tried for
treating patients with PH, such as anticoagulant and vaso-
dilator agents (2,3). Anticoagulants are believed to reduce
in situ thrombosis in the pulmonary circulation, and thus
the progression of this disease may be slowed (2). As
vasodilator agents, calcium-channel blockers have been used
to reduce vasoconstriction of the pulmonary vasculature (3).
Furthermore, other treatments, such as inotropic agents,
diuretics and oxygen supplementation, have been used for
patients with PH. All of these conventional therapies are
partially effective in some patients; however, none of them
has resulted in improved survival (4).
Prostacyclin (PGI2) is a potent, short-acting vasodilator
and inhibitor of platelet aggregation that is endogenously
produced by the vascular endothelium (5). Vascular tone is
maintained by the balance of vasodilative and vasoconstric-
tive prostanoids released by platelets and, to a considerable
extent, the vascular endothelium (6). An imbalance in the
production of PGI2, a vasodilator, and thromboxane A2
(TXA2), a vasoconstrictor, in the pulmonary circulation
exists in patients with PH, and this seems to cause the
progression of PH (6,7). It has been reported that intrave-
nous (IV) PGI2 infusion significantly reduces pulmonary
arterial pressure and pulmonary vascular resistance in pa-
tients with PH (5,8). Recently, continuous IV infusion of
PGI2 was reported to improve exercise capacity (4,9) and
long-term survival in patients with PH (4,10), in addition to
lowering pulmonary vascular resistance (11). However, it
must be given continuously through a central IV catheter
infusion system, which may be associated with serious
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complications, including recurrent IV route infections,
blood clotting and severe systemic hypotension (1,4).
Beraprost sodium (BPS) is a chemically stable oral PGI2
analogue whose pharmacologic profile is similar to that of
PGI2 (12–14). It was reported that BPS has a protective
effect on the development of PH in animal models (12), and
that BPS is effective in patients with primary and secondary
PH (13,15). However, the effectiveness of BPS is limited
and is not sufficient to treat all patients with PH.
Endothelin (ET)-1, a potent vasoconstrictor peptide
derived from endothelial cells (16,17), induces the growth of
vascular smooth muscle cells (17,18) and myocardial cell
hypertrophy (17,18). The plasma ET-1 level is reported to
be increased in patients with PH, and ET-1 is thought to
play an important role in the progression of PH (19). We
have reported that the expression of ET-1 in the lungs of
rats with PH due to congestive heart failure was markedly
increased (20) and that the high plasma ET-1 concentration
in patients with PH due to congenital heart disease was
normalized by successful surgical repair, accompanied by a
marked improvement of pulmonary hemodynamics (21).
These observations suggest that endogenous ET-1 may
contribute to the increase in pulmonary vascular tone in
patients with PH. Furthermore, we have shown that an
ETA receptor antagonist inhibited the progression of PH
and ameliorated the vascular thickening, RV hypertrophy
and poor survival in rats with PH induced by monocrotaline
(MCT) (22,23). We have also reported that an ETA
receptor antagonist improved PH associated with congestive
heart failure (20). It was reported that acute ET receptor
blockade caused selective pulmonary vasodilation in human
patients with PH due to chronic heart failure (24). Recently,
in patients with PH (primary or associated with scleroder-
ma), it was reported that long-term treatment with an ET
receptor antagonist increased exercise capacity and im-
proved hemodynamics (25). These findings suggest that an
ET receptor antagonist is alternative treatment for PH, as
well as oral PGI2 analogues.
We hypothesized that the combination of an oral ETA
receptor antagonist and an oral PGI2 analogue would be
more effective than the single use of each drug alone for
ameliorating PH. Therefore, we investigated the effective-
ness of these two drugs in reducing the progression of PH
in an animal model, alone and in combination. A single
subcutaneous injection of MCT, a pyrrolizidine alkaloid,
causes pulmonary vascular endothelial cell damage and
medial wall thickening of muscular pulmonary arteries,
which lead to PH (22,26–28). Therefore, we used MCT-
treated rats as a PH model in this study.
METHODS
Study protocols. First, four-week-old male Wistar rats
were given a single subcutaneous injection of 60 mg/kg
MCT (Wako Pure Chemical, Osaka, Japan) (PH rats) or
saline (normal rats), according to our previously described
report (22,26,27). The ETA receptor antagonist TA-0201
(29,30) and/or the PGI2 analogue BPS (14), or vehicle was
administered orally once per day from the day before MCT
injection to 19 days after. Rats were evaluated 1, 7, 14 and
19 days after injection by two-dimensional echocardiogra-
phy. Nineteen days after the start of treatment, hemody-
namics were evaluated; the heart was excised and divided
into the RV, interventricular septum and left ventricle (LV).
The lungs were also excised and immersed in 10% buffered
formalin for histologic evaluation.
Second, to determine the inhibitory effect of these drugs,
which were started after the onset of PH, on disease
progression, we administered the drugs from 10 days (after
the onset of PH [22]) to 19 days after MCT injection.
Third, to determine whether the use of a higher dose of
each drug can reach the ameliorating effect on PH progres-
sion obtained by the combination treatment of both drugs,
the rats were treated with a higher dose of each drug from
1 day before to 19 days after MCT injection.
The study was approved by the Laboratory Animal
Resource Center of the University of Tsukuba and con-
formed to the “Position of the American Heart Association
on Research Animal Use,” adopted by the American Heart
Association on November 11, 1984.
Study groups. First, the rats were classified into the fol-
lowing five groups: 1) normal rats administered vehicle
(Control group, n  12); 2) PH rats administered vehicle
(PH group, n  17); 3) PH rats administered the oral ETA
receptor antagonist TA-0201 (synthesized by Tanabe Seiy-
aku Co. Ltd., Saitama, Japan) at 0.5 mg/kg/day (PH  TA
group, n  18); 4) PH rats administered the oral PGI2
analogue BPS (donated by Yamanouchi Pharmaceutical Co.
Ltd., Tokyo, Japan) at 100 g/kg/day (PH  BPS group,
n  13); and 5) PH rats administered TA-0201
(0.5 mg/kg/day) and BPS (100 g/kg/day) (PH  TA 
BPS group, n  18). The drugs were started the day before
MCT injection.
Second, the effect of these drugs starting after the onset of
Abbreviations and Acronyms
BPS  beraprost sodium
BW  body weight
ET  endothelin
IV  intravenous
LV  left ventricle/ventricular
MCT  monocrotaline
MHC  myosin heavy chain
mRNA  messenger ribonucleic acid
PGI2  prostacyclin
PH  pulmonary hypertension/hypertensive
Pp/Ps  ratio of right ventricular systolic pressure to
systemic systolic blood pressure
RT-PCR  reverse transcription-polymerase chain
reaction
RV  right ventricle/ventricular
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PH (10 days after MCT injection) was also investigated in
the same groups: 1) Control group, n  6; 2) PH group,
n  7; 3) PH  TA group; n  7; 4) PH  BPS group,
n  7; and 5) PH  TA  BPS group, n  8.
Third, experiments using higher doses of these drugs
were also performed: 1) Control group, n 6; 2) PH group,
n  8; 3) PH  TA group (TA-0201 at 1.0 mg/kg/day),
n  9; 4) PH  BPS group (BPS at 200 g/kg/day), n 
8; and 5) PH  TA  BPS group (TA-0201 at
1.0 mg/kg/day; BPS at 200 g/kg/day), n  8. The drugs
were started the day before MCT injection.
Two-dimensional echocardiography. The rats were laid
on their back under anesthesia with diethyl ether. Two-
dimensional echocardiography was performed with an echo-
cardiographic system (Model SSD-900, Aloka, Tokyo,
Japan) and a 7.5-MHz probe (UST-987-7.5, Aloka). In the
parasternal echocardiographic window, a two-dimensional
short-axis view of the LV was obtained at the level of the
papillary muscle. To estimate the increase in RV systolic
pressure, we calculated the ratio of the minor axis to the
major axis of the LV in the end-systolic phase (31).
Measurements were performed by a single observer.
Hemodynamic measurements. Hemodynamic parameters
were measured according to our previous reports, with
minor modifications (20,22,27,30). The rats were anesthe-
tized with sodium pentobarbital (50 mg/kg intraperitoneal-
ly). Arterial blood pressure and heart rate were monitored
with a polyethylene catheter inserted into the right carotid
artery, and another polyethylene catheter was inserted into
the right jugular vein and advanced into the RV for
measurement of RV pressure (AP-601G amplifier and
WT-687G thermal pen recorder, Nihon Koden, Tokyo,
Japan).
Reverse transcription polymerase chain reaction (RT-
PCR). Total ribonucleic acid (RNA) from the RV was
isolated by acid guanidinium thiocyanate/phenol/
chloroform extraction with ISOGEN (Nippon Gene Ltd.,
Tokyo, Japan), and the messenger RNA (mRNA) levels
were analyzed by RT-PCR, according to our previous
methods (27,30,32). In the myocardium, there are two
subunits of myosin heavy chain (MHC): alpha-MHC and
beta-MHC. A distinction between alpha-MHC and beta-
MHC was made by employing our previous method (32)
using a PCR thermal cycler (TP-3000, TaKaRa Ltd., Otsu,
Japan). The sequences of the oligonucleotides, which are
identical to both subunits, were as follows: MHC (sense):
5GCAGACCATCAAGGACCT3; and MHC (anti-
sense): 5 GTTGGCCTGTTCCTCCGCC3.
The PCR reaction mixture was digested with MseI (New
England Biolabs, Inc., Beverly, Massachusetts); the PCR
product of alpha-MHC was not digested, whereas that of
beta-MHC was digested. The amplified products on aga-
rose gels were stained with ethidium bromide, visualized by
an ultraviolet transilluminator and photographed. The pho-
tograph was scanned by a scanner (CanoScan 600, Canon
Ltd., Tokyo, Japan), and quantification was performed
using MacBAS software (FUJI FILM Ltd., Tokyo, Japan)
(27,30,32).
Histologic examination of the lungs. Paraffin sections of
4 m thickness from each left lung stained with azan were
examined under light microscopy. Pulmonary arteries with
an external diameter of about 50 m were scanned, and
medial wall thickness was determined on a personal com-
puter with MacScope software (Mitani Ltd., Fukui, Japan),
according to our previous methods (22). The ratio of medial
wall thickness to external diameter of each artery was
calculated and evaluated in each group.
Statistical analysis. All data were expressed as the mean
value SE. All statistical comparisons were performed with
a statistical package for Macintosh personal computer
(STAT VIEW, version 4.5, Abacus Concepts Inc., Berke-
ley, California). The significance of differences was analyzed
by using Kruskal-Wallis one-way analysis of variance, fol-
lowed by the Fisher test of protected least significant
differences for multiple comparisons. The results were
considered statistically significant at p  0.05.
RESULTS
Time course of PH evaluated by two-dimensional echo-
cardiography. Changes in the ratio of the minor axis to the
major axis of the LV in the end-systolic phase in PH rats
treated with the moderate doses of drugs are shown in
Figure 1. The ratio in the Control (healthy) group did not
change by days 7, 14 and 19 from baseline (day 1) (Fig. 1).
The ratio in the PH group was markedly decreased by day
14, and the ratio had further decreased by day 19 (Fig. 1).
By day 19, the decrease in the ratio in the PH  TA and
PH  BPS groups was inhibited to a similar extent as that
in the PH group (Fig. 1). The decrease in the ratio in the
PH  TA  BPS group was inhibited to the greatest
degree among the three PH groups with treatments (Fig. 1).
Hemodynamic measurements. Right ventricular systolic
pressure and the ratio of RV systolic pressure to systemic
systolic blood pressure (Pp/Ps), an index of PH, were much
greater in the PH group than in the Control group (Fig. 2).
The indexes were comparably lower in the PH  TA and
PH  BPS groups than in the PH group and were lowest
in the PH TA BPS group among the three PH groups
with treatments (Fig. 2). In rats treated with higher doses of
drugs, the percent change of increase in RV systolic pressure
was following: PH  TA, 60%; PH  BPS, 54%; and
PH  TA  BPS, 25% (these percentages represent the
change of increase as it relates to 100% in the PH group and
0% in the Control group). It showed the same tendency and
similar extent as that in rats treated with moderate doses of
drugs. In rats treated with moderate doses of drugs starting
after the onset of PH, the percent change of increase in RV
systolic pressure was following: PH  TA, 65%; PH 
BPS, 83%; and PH  TA  BPS, 53%. The suppressive
degree of increase in RV systolic pressure in the PH 
TA  BPS group starting after the onset of PH was
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significant but small compared with that staring before the
onset of PH.
Weight measurements. The ratios of RV wet weight to
body weight (BW) and RV wet weight to LV wet weight
were markedly higher in the PH group than in the Control
group (Fig. 3). The ratios were comparably lower in the
PH  TA and PH  BPS groups than in the PH group
and were lowest in the PH  TA  BPS group among the
three PH groups with treatment (Fig. 3). In rats treated
with higher doses of drugs, the degree of increase in the
RV/BW ratio was following: PH  TA, 63%; PH  BPS,
62%; and PH  TA  BPS, 35% (these percentages
represent the change of increase as it relates to 100% the
value in the PH group and 0% in the Control group). It
showed the same tendency and similar extent as that in rats
treated with moderate doses of drugs. In rats treated with
moderate doses of drugs starting after the onset of PH, the
degree of increase in the RV/BW ratio was following:
PH TA, 94%; PH BPS, 110%; and PH TA BPS,
74%. The suppressive degree of increase in the RV/BW
ratio in the PH  TA  BPS group starting after onset of
PH was significant but small compared with that starting
before the onset of PH.
Expression of alpha- and beta-MHC mRNA in the RV.
We used the ratio of the expression of beta-MHC mRNA
to alpha-MHC mRNA as a molecular marker for ventric-
ular hypertrophy. In the first series of experiments, the ratio
of the expression of beta-MHC mRNA to alpha-MHC
mRNA in the RV was markedly higher in the PH group
(Fig. 4). The increase was comparably depressed in the PH
 TA and PH BPS groups compared with the PH group
(Fig. 4). Furthermore, the ratio was almost normalized in
the PH  TA  BPS group compared with the Control
group (Fig. 4).
Histologic examination of the lungs. Medial wall thick-
ness was about 1.4-fold greater in the PH group than in the
Control group (Figs. 5 and 6). The ratio tended to be lower
in the PH  TA and PH  BPS groups than in the PH
group (vehicle treatment); however, it showed no significant
difference statistically (Fig. 6). In contrast, the ratio was
lowest in the PH  TA  BPS group among the three PH
treatment groups, and statistical significance was observed
between the PH group and the PH  TA  BPS group
(Figs. 5 and 6).
DISCUSSION
Superiority of combination treatment over single use of
each drug. The present study revealed that, in PH rats, the
combination of an ETA receptor antagonist and a PGI2
analogue is more effective than the single use of each drug
alone in inhibiting the progression of PH. This conclusion
is derived from the following results: 1) the combination of
an ETA receptor antagonist and a PGI2 analogue inhibited
the increase in RV systolic pressure and Pp/Ps to a greater
degree than was obtained with either drug alone in PH rats,
and these data were also supported by the results of
echocardiography; 2) the combination of these drugs inhib-
ited medial wall thickening of the pulmonary artery to a
greater degree than was obtained with either drug alone; and
3) the combination of these drugs inhibited RV hypertrophy
to a greater degree than was obtained with either drug alone,
which was in accordance with the increased expression of
beta-MHC mRNA. The present study also showed that
combined treatment ameliorated PH, even if it started after
the onset of PH. Furthermore, higher doses of these drugs
(see Results) prevented PH progression to the same extent
as moderate doses (Figs. 1 to 6). The use of a higher dose of
either drug could not achieve the ameliorating effect of the
combination treatment. Thus, the combination treatment is
superior to the single use of each drug alone in ameliorating
PH.
Mechanisms for favorable effects of combination treat-
ment on pulmonary circulation. Beraprost sodium sup-
plies PGI2 to the pulmonary circulation, whereas TA-0201
blocks the binding of ET-1 to ETA receptors. The signal
transduction system differs between PGI2 and ET-1: PGI2
activates adenylate cyclase and increases cyclic adenosine
monophosphate, which decreases intracellular Ca2 (33),
whereas ET-1 activates phospholipase C and diacylglycerol,
followed by an increase in inositol triphosphate and activa-
tion of protein kinase C, which increases intracellular Ca2
(17). Thus, the supplementation of PGI2 by BPS and
blockade of ET-1 binding by TA-0201 may decrease
Figure 1. Changes in the ratio of the minor axis (a) of left ventricle (LV)
to the major axis (b) of the LV, an index of pulmonary hypertension (PH),
in the parasternal short-axis view of the LV by two-dimensional echocar-
diography. The view was obtained at the level of the papillary muscle. It
was evaluated on days 1, 7, 14 and 19 after the start of treatment. Control
group (open circles, n 12); PH group (solid circles, n 17); PH TA
group (open squares, n  18); PH  BPS group (solid squares, n  13);
and PH  TA  BPS group (open diamonds, n  18). *p  0.05 vs.
Control group. §p  0.05 vs. PH group. #p  0.05 vs PH  TA  BPS
group. ¶p  0.05 vs. baseline value of each group on day 1. Data are
presented as the mean value  SE. BPS  beraprost sodium; PH 
pulmonary hypertension; RV  right ventricle; TA  TA-0201.
178 Ueno et al. JACC Vol. 40, No. 1, 2002
Combination of ETA Blocker and PGI2 Analogue in PH July 3, 2002:175–81
intracellular Ca2 and dilate the pulmonary arteries through
the additional mechanism of each compound. Furthermore,
there is a possibility of an interaction between PGI2 and
ET-1 in the induction of gene expression; for example,
PGI2 is reported to inhibit expression of the ET-1 gene in
endothelial cells (17,34) and ET-1–induced deoxyribonu-
cleic acid synthesis in vascular smooth muscle cells (35).
Therefore, the combined use of two compounds may inhibit
the development of PH additionally and synergistically,
partly through ablating the pharmacologic action of ET-1.
Pathophysiologic involvement of the PGI2 and ET-1
pathways in PH. One of the assumed mechanisms of the
development of PH is impairment of vascular endothelial
cell function of the pulmonary vasculature (6). Pulmonary
vascular endothelial dysfunction leads to an imbalance of the
production of PGI2 and TXA2 (decrease in PGI2 and
increase in TXA2), and this discrepancy is considered to
cause vascular spasm of pulmonary capillary vessels and
microthrombus formation (6,7,36). The administration of
BPS supplies PGI2 to the pulmonary circulation in PH rats;
therefore, vasospasm and generation of microthrombus may
be inhibited. Thus, PH is ameliorated by the administration
of BPS.
Activation of the ET-1 pathway in the pulmonary circu-
lation is assumed to be involved in the progression of PH
(19,22). We previously reported that the increase in pulmo-
nary arterial pressure is partly attributable to the potent
vasoconstrictive action of ET-1 (26). In addition, ET-1 has
a potent proliferative effect on vascular smooth muscle cells
(17,18), suggesting that the increase in pulmonary vascular
resistance and pulmonary arterial pressure may be partly due
to vascular smooth muscle cell proliferation and narrowing
Figure 2. Right ventricular systolic pressure (left) and Pp/Ps ratio (right) in the Control group (n  12), PH group (n  17), PH  TA group (n  18),
PH  BPS group (n  13) and PH  TA  BPS group (n  18). *p  0.05 vs. Control group. §p  0.05 vs. PH group. #p  0.05 vs. PH  TA 
BPS group. Each column and bar represents the mean value  SE. BPS  beraprost sodium; PH  pulmonary hypertension; TA  TA-0201.
Figure 3. Ratio of right ventricular (RV) wet weight to BW (left) and ratio of RV wet weight to left ventricular (LV) wet weight (right) in the Control
group (n  12), PH group (n  17), PH  TA group (n  18), PH  BPS group (n  13) and PH  TA  BPS group (n  18). *p  0.05 vs. Control
group. §p  0.05 vs. PH group. #p  0.05 vs. PH  TA  BPS group. Each column and bar represents the mean  SE. BPS  beraprost sodium; PH 
pulmonary hypertension; TA  TA-0201.
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of the lumen. Therefore, administration of TA-0201 sup-
presses the progression of PH by inhibiting the proliferation
of pulmonary vascular smooth muscle cells, as well as by
inhibiting vasoconstriction of the pulmonary vasculature.
Mechanisms for favorable effects of combination treat-
ment on RV hypertrophy. One of the mechanisms of
inhibition of RV hypertrophy is considered to be the
reduction in pulmonary arterial pressure and pulmonary
vascular resistance by these compounds. Endothelin-1 is
produced by cardiac myocytes and has a potent cardiac
hypertrophic effect both in vitro and in vivo (6,17,18). We
have also reported that pressure overload increases the
production of ET-1 in the heart and that the expression of
ET-1 mRNA is elevated in the hypertrophied RV of PH
rats (22,27). Thus, another mechanism for the inhibition of
RV hypertrophy is suspected to be partly attributable to
TA-0201’s interference with the direct action of ET-1 on
cardiac hypertrophy. Furthermore, as PGI2 suppresses the
induction of the ET-1 gene (17,34), the administration of
both compounds may inhibit RV hypertrophy additionally
and synergistically. Therefore, the administration of both
compounds is considered to be a good combination for the
treatment of RV hypertrophy and PH, because excessive
hypertrophy of the RV is regarded as a risk factor for right
heart failure, which is associated with high morbidity and
mortality (1).
Clinical implications. The present study showed that the
combination of an oral ETA receptor antagonist and an oral
PGI2 analogue was superior to the single use of each drug
alone in inhibiting the progression of PH in rats. As
mentioned earlier, IV infusion of PGI2 is an effective
therapy for patients with PH, however, it must be given
continuously through a central IV line, and therefore several
complications may develop (1,4). Thus, the use of orally
available drugs is expected to become the norm, and the
Figure 4. Ratio of expression level of beta-myosin heavy chain (MHC)
messenger ribonucleic acid (mRNA) to alpha-MHC mRNA in the right
ventricle in the Control group (n  12), PH group (n  17), PH  TA
group (n  18), PH  BPS group (n  13) and PH  TA  BPS group
(n  18). A typical example of the reverse transcription (RT)-polymerase
chain reaction (PCR) product in each group is also shown. *p  0.05 vs.
Control group. §p  0.05 vs. PH group. #p  0.05 vs. PH  TA  BPS
group. Each column and bar represents the mean value  SE. BPS 
beraprost sodium; PH  pulmonary hypertension; TA  TA-0201.
Figure 5. Photomicrographs of the pulmonary arteries in the Control group (A), PH group (B) and PH  TA  BPS group (C). Histologic examination
of the lung showed a marked increase in pulmonary arterial medial wall thickening in the PH group. The increase in the thickening was attenuated in the
PH  TA  BPS group. Each section was stained with Azan (520). BPS  beraprost sodium; PH  pulmonary hypertension; TA  TA-0201.
Figure 6. Ratio of medial wall thickness to the external diameter of the
pulmonary arteries of rats in the Control group (n  12), PH group (n 
17), PH TA group (n 18), PH BPS group (n 13) and PH TA
 BPS group (n  18). Pulmonary arteries with an external size of
about 50 m were chosen. *p  0.05 vs. Control group. §p  0.05 vs. PH
group. #p  0.05 vs. PH  TA  BPS group. Each column and bar
represents the mean value  SE. BPS  beraprost sodium; PH 
pulmonary hypertension; TA  TA-0201.
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combined use of an orally available ETA receptor antagonist
and an orally available PGI2 analogue is considered to
become an important strategy, rather than continuous IV
infusion of PGI2 alone. Furthermore, the present study also
showed that combined therapy ameliorates PH, even if it
starts after the onset of PH, and this condition is commonly
found in the clinical setting.
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